Brookline Capital Markets Maintains $506 PT and Buy Rating on Moderna (MRNA), Annouced Data 'Supports Our Outlook'
Go back to Brookline Capital Markets Maintains $506 PT and Buy Rating on Moderna (MRNA), Annouced Data 'Supports Our Outlook'Marina Biotech, Inc. (NASDAQ: MRNA) | Delayed: 106.18 -2.67 (2.45%) | |||||
---|---|---|---|---|---|---|
Previous Close | $108.85 | 52 Week High | $0.52 | |||
Open | $107.43 | 52 Week Low | $0.08 | |||
Day High | $108.19 | P/E | N/A | |||
Day Low | $103.52 | EPS | $-3.80 | |||
Volume | 2,797,974 |